Futura Medical Provides Update on Block Listings and Shares Issued

Futura Medical PLC, a pharmaceutical company developing sexual health products, has provided an update on its block listings. The company has four schemes: Unapproved Share Option Scheme, Unapproved Share Incentive Scheme, EMI Share Option Scheme, and LTIP Scheme. The balance of unallotted securities under these schemes from the previous return was 12,526,721. During the period from 1 June 2023 to 30 November 2023, the LTIP scheme was increased by 10,590,675 securities. The number of securities issued/allotted under the schemes during the period were as follows: USOS (nil), EMI (756,000), and LTIP (1,578,731). The balance under the schemes not yet issued/allotted at the end of the period is 20,782,665.

The news release also provides details of the number and class of securities originally admitted and the date of admission for each scheme. The USOS scheme has a total of 3,882,912 securities, with various admission dates ranging from 25 May 2011 to 30 May 2018. The USIS scheme has a total of 425,000 securities, admitted on 30 November 2018. The EMI scheme has a total of 8,112,088 securities, admitted on various dates from 25 May 2011 to 2 February 2023. The LTIP scheme has a total of 15,035,617 securities, admitted on 2 February 2023 and 3 November 2023.

For further information, investors can contact Futura Medical PLC or its Nominated Adviser and Sole Broker, Liberum. Media enquiries can be directed to Optimum Strategic Communications.

Futura Medical PLC is a pharmaceutical company focused on developing innovative products based on its proprietary transdermal DermaSys® technology. The company's products are developed for the prescription and consumer healthcare markets. Its lead product, MED3000, is a topical gel formulation for the treatment of erectile dysfunction (ED). Futura has conducted two Phase 3 studies using MED3000, which demonstrated its effectiveness and safety profile. The company also has a product called Eroxon®, which is FDA approved in the US and CE marked in Europe and the UK for the treatment of adult men with ED.